T2 Biosystems to Unveil New Data at September Conferences
September 14 2021 - 10:05AM
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection
of sepsis-causing pathogens, today announced it will unveil new
data at industry conferences this month to showcase results and
implications of the use of its rapid diagnostics technologies.
"We are committed to developing a library of clinical research
to support and highlight the value of culture-independent rapid
diagnostics for use in the detection and treatment of sepsis,
especially during Sepsis Awareness Month and at a time when sepsis
is top-of-mind as a common complication of COVID-19,” said John
Sperzel, Chairman and Chief Executive Officer of T2 Biosystems. “We
are pleased to share new data with healthcare professionals and
lead important, life-saving conversations within the medical
community.”
T2 Biosystems is the presenting sponsor of the
second annual Sepsis Alliance Summit, a virtual summit hosted by
Sepsis Alliance from September 14 – 16 that explores sepsis-related
topics in healthcare. On Tuesday, September 14 at 10:30 a.m. ET,
John Sperzel, Chairman and Chief Executive Officer of T2
Biosystems, will share his journey as a heart transplant recipient
and sepsis survivor, leading an opening session titled “Rapid
Diagnostics and the Impact on Sepsis.” At 11:30 a.m. ET, Aparna
Ahuja, MD, Chief Medical Officer at T2 Biosystems, will lead the
session, “Culture-Independent Testing: A New Way to Hurdle
Obstacles for Detection of Sepsis-Causing Pathogens and Improve
Patient Outcomes” with a focus on incorporating T2Panels into
clinical care and performance evaluations of T2Resistance RUO at
leading medical institutions. The Company will also host a virtual
booth as part of the exhibition.
At the American Association for Clinical Chemistry’s Annual
Scientific Meeting and Clinical Lab Expo, which will showcase
cutting-edge science and technology shaping the future of
laboratory medicine from September 26 – 30, the Company will
present two abstracts with new findings on rapid diagnostics.
First, “Impact of Blood Culture-Independent Rapid Diagnostics on
Early Identification of Sepsis-Causing Pathogens” will be presented
by Aparna Ahuja, MD, Chief Medical Officer and second, “Development
of a Rapid, High Sensitivity, Direct from Blood Assay for
Identification of Biothreat Organisms” will be presented by Robert
Shivers, PhD, Director of Microbiology at T2 Biosystems. On
Tuesday, September 28 at 3:30 p.m. ET, T2 Biosystems’ Aparna Ahuja,
MD, Chief Medical Officer will also host a scientific workshop
titled, “It’s a New Era: Culture-Independent Tests for Rapid
Detection of Sepsis-Causing Pathogens that Lead to Positive
Healthcare Outcomes.”
The College of American Pathologists' Annual Meeting will be
held from September 25-28. “T2SARS-CoV-2 Panel is Able to Detect
All SARS-CoV-2 Variants as Confirmed by Genomic Surveillance” and
“Utilization of a Novel Diagnostic Assay to Improve Turnaround Time
and Accurate Diagnosis and Treatment of Secondary Candidemia in a
Critically Ill Immunosuppressed COVID-19 Patient” will be presented
at the College of American Pathologists' Annual Meeting.
To close out Sepsis Awareness Month, T2 Biosystems will
present new data at IDWeek. ID Week is taking place virtually
between September 29 and October 3. The “Performance of the
T2Resistance® Panel in Detecting Antibiotic Resistant Bacteria
Directly in Whole Blood, and Implications for Improving Appropriate
Therapy of Bloodstream Infections” will be presented at ID
Week.
For those interested in the Company’s data, visit
https://www.t2biosystems.com/news-resources/publications/ following
the conferences.
About T2 BiosystemsT2 Biosystems, a leader in
the rapid detection of sepsis-causing pathogens, is dedicated to
improving patient care and reducing the cost of care by helping
clinicians effectively treat patients faster than ever before. T2
Biosystems’ products include the T2Dx® Instrument, T2Candida®
Panel, the T2Bacteria® Panel, the T2Resistance® Panel, and the
T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic
Resonance (T2MR®) technology. T2 Biosystems has an active pipeline
of future products, including the T2Cauris™ Panel, and T2Lyme™
Panel, as well as additional products for the detection of
bacterial and fungal pathogens and associated antimicrobial
resistance markers, and biothreat pathogens.
Media Contact:Meagan Dominick, Vault
Communicationsmdominick@vaultcommunications.com 773-369-4255
Investor Contact:Philip Trip Taylor, Gilmartin
Groupphilip@gilmartinIR.com 415-937-5406
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Mar 2024 to Apr 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Apr 2023 to Apr 2024